Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- David Witt, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Justin Persico, MD
- Katherine Harvey, MD, MPH
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Laura Van Metre Baum, MD, MPH
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Robert Legare, MD
- Samantha Couillard
- Sara Anastasio, RN
- Stacey Stein, MD
- Stephen Lattanzi, MD
- Teresa White
- Victor Chang, MD
- Virginia Syombathy
- Last Updated12/22/2022
- Study HIC#2000032098